Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers.
Two hundred female sex workers (FSWs) in Lima, Peru were randomized to receive HPV4 vaccine in the standard (0, 2, 6 months) or a modified schedule (0, 3, 6 months). One hundred and eighty four (92%) participants completed 3 doses of vaccine. Baseline seropositive rates were 58% for HPV6, 22.5% for HPV11, 41.5% for HPV16, and 13% for HPV18. The final geometric mean antibody titer (GMT) following vaccination was significantly greater for women who were seropositive at baseline compared to seronegative women: HPV6 (GMT ratio=2.3, p<0.01), HPV11 (GMT ratio=2.7, p<0.01), HPV16 (GMT ratio=1.3, p=0.04), and HPV18 (GMT ratio=2.4, p<0.01). Antibody titers in the modified schedule were not inferior to those in the standard schedule, suggesting the modified schedule may be paired with required STD visits. Although all women benefit from vaccination, administration at a younger age and before sexual debut is needed to achieve maximum protection from vaccine.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. bjbrown@ucla.edu
Brandon
B
Brown
Magaly
M
Blas
Alejandra
A
Cabral
Cesar
C
Carcamo
Patti
P
Gravitt
Neal
N
Halsey
D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D000914:Antibodies, Viral / Q000097:blood*; D002584:Cervix Uteri / Q000821:virology; D005260:Female; D052689:Gammapapillomavirus / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D010568:Peru; D060386:Sex Workers; D016896:Treatment Outcome; D014611:Vaccination; D055815:Young Adult
D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines